A Birmingham-based molecular diagnostics company announced on April 3 it has received FDA emergency authorization to produce and distribute a new diagnostic test that will enable hospitals to screen for COVID-19. BioGX Inc. made the announcement in conjunction with BD (Becton, Dickinson and Co. — NYSE: BDX), a leading global medical technology company. BioGX’s new…
